Monitoring
Patients with AML should be closely monitored for recurrence of the disease and development of complications.
For patients with an AML-defining genetic abnormality detected at diagnosis, testing for the abnormality should be repeated during and after completion of treatment to monitor for residual disease.[24] For patients without such abnormalities, regular routine full blood count to detect any cytopenias is recommended.
Use of this content is subject to our disclaimer